Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Oprozomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 25 Sep 2019 Status changed from active, no longer recruiting to completed.
- 08 Aug 2019 Planned End Date changed from 31 Jul 2019 to 23 Sep 2019.
- 08 Aug 2019 Planned primary completion date changed from 31 Jul 2019 to 23 Sep 2019.